Prosensa Holding

Prosensa Holding B.V. developed therapeutics on the basis of RNA modulation, thereby intervening in an intermediate step in protein biosynthesis.

The company’s lead program was in Duchenne Muscular Dystrophy (DMD), a genetic disorder that blocks the synthesis of an important protein. DMD leads to progressive paralysis and eventually to death.

Portfolio: MedSciences Capital B.V. and MedSciences Capital II B.V.

Current stage: Acquired by Biomarin.